FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1639292827> ?p ?o ?g. }

• W1639292827 endingPage "1477" @default.
• W1639292827 startingPage "1469" @default.
• W1639292827 abstract "Ticagrelor is recommended in local and international guidelines as first-line therapy in combination with aspirin in patients presenting with acute coronary syndromes (ACS). The purpose of this article is to provide practical guidance regarding the use of ticagrelor in this setting.Ticagrelor, a direct-acting, reversible P2Y12 receptor antagonist, has a faster onset, and a more potent and predictable antiplatelet effect compared with clopidogrel. The authors recommend considering the use of ticagrelor in moderate-to-high risk ACS patients treated with an invasive approach and those managed non-invasively who have elevated troponin levels. Consistent with outcomes observed in the PLATO trial overall, ticagrelor was superior to clopidogrel treatment in patients with chronic kidney disease, a history of stroke or transient ischemic attack, the elderly, and patients requiring surgical revascularization.When switching from clopidogrel to ticagrelor, patients established on clopidogrel therapy can be switched directly without loading; patients not loaded with clopidogrel and not taking maintenance dose clopidogrel for at least 5 days should first be loaded with ticagrelor. Guidelines recommend discontinuing ticagrelor 5 days before surgery if antiplatelet effects are not desired and recommencing therapy as soon as safe following surgery. Ticagrelor should be avoided in individuals with a history of intracranial hemorrhage, moderate-to-severe hepatic impairment, high bleeding risk, within 24 hours of thrombolytic therapy, and in those treated with oral anticoagulants. Local, real-world experience suggests low bleeding rates with ticagrelor therapy. Dyspnoea is a common symptom in patients with ACS and is also a side-effect of ticagrelor therapy. Discontinuation of ticagrelor due to dyspnoea has been uncommon in clinical trials. However, local registry data suggest higher discontinuation rates (2-9%) related to dyspnoea in the real-world setting, indicating that clinicians may need to consider other potential causes of dyspnoea before discontinuing ticagrelor." @default.
• W1639292827 created "2016-06-24" @default.
• W1639292827 creator A5005852503 @default.
• W1639292827 creator A5006931797 @default.
• W1639292827 creator A5009735463 @default.
• W1639292827 creator A5018756121 @default.
• W1639292827 creator A5033070568 @default.
• W1639292827 creator A5045399615 @default.
• W1639292827 creator A5078927662 @default.
• W1639292827 date "2015-06-29" @default.
• W1639292827 modified "2023-10-17" @default.
• W1639292827 title "Practical experience with ticagrelor: an Australian and New Zealand perspective" @default.
• W1639292827 cites W11440812 @default.
• W1639292827 cites W136622145 @default.
• W1639292827 cites W1931695288 @default.
• W1639292827 cites W1947134634 @default.
• W1639292827 cites W1972679886 @default.
• W1639292827 cites W1973577494 @default.
• W1639292827 cites W1980162439 @default.
• W1639292827 cites W1987347720 @default.
• W1639292827 cites W1994370396 @default.
• W1639292827 cites W1996664577 @default.
• W1639292827 cites W2001688139 @default.
• W1639292827 cites W2024656127 @default.
• W1639292827 cites W2026997625 @default.
• W1639292827 cites W2035255052 @default.
• W1639292827 cites W2039230140 @default.
• W1639292827 cites W2045713748 @default.
• W1639292827 cites W2048216325 @default.
• W1639292827 cites W2048456880 @default.
• W1639292827 cites W2059341294 @default.
• W1639292827 cites W2064667702 @default.
• W1639292827 cites W2068426257 @default.
• W1639292827 cites W2082069148 @default.
• W1639292827 cites W2085260510 @default.
• W1639292827 cites W2087951913 @default.
• W1639292827 cites W2107797912 @default.
• W1639292827 cites W2109577952 @default.
• W1639292827 cites W2121178468 @default.
• W1639292827 cites W2125043491 @default.
• W1639292827 cites W2125173296 @default.
• W1639292827 cites W2126841320 @default.
• W1639292827 cites W2127918456 @default.
• W1639292827 cites W2129707460 @default.
• W1639292827 cites W2131181128 @default.
• W1639292827 cites W2131184211 @default.
• W1639292827 cites W2140501627 @default.
• W1639292827 cites W2141358924 @default.
• W1639292827 cites W2150858828 @default.
• W1639292827 cites W2153107785 @default.
• W1639292827 cites W2153443504 @default.
• W1639292827 cites W2156255513 @default.
• W1639292827 cites W2157184686 @default.
• W1639292827 cites W2159370853 @default.
• W1639292827 cites W2160205454 @default.
• W1639292827 cites W2160952754 @default.
• W1639292827 cites W2161055506 @default.
• W1639292827 cites W2168722424 @default.
• W1639292827 cites W2169387542 @default.
• W1639292827 cites W2170029016 @default.
• W1639292827 cites W2170260872 @default.
• W1639292827 cites W2546593930 @default.
• W1639292827 cites W3030817736 @default.
• W1639292827 cites W3184177771 @default.
• W1639292827 cites W4236531408 @default.
• W1639292827 cites W4240958118 @default.
• W1639292827 doi "https://doi.org/10.1185/03007995.2015.1058247" @default.
• W1639292827 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26086451" @default.
• W1639292827 hasPublicationYear "2015" @default.
• W1639292827 type Work @default.
• W1639292827 sameAs 1639292827 @default.
• W1639292827 citedByCount "8" @default.
• W1639292827 countsByYear W16392928272015 @default.
• W1639292827 countsByYear W16392928272016 @default.
• W1639292827 countsByYear W16392928272017 @default.
• W1639292827 countsByYear W16392928272018 @default.
• W1639292827 countsByYear W16392928272020 @default.
• W1639292827 crossrefType "journal-article" @default.
• W1639292827 hasAuthorship W1639292827A5005852503 @default.
• W1639292827 hasAuthorship W1639292827A5006931797 @default.
• W1639292827 hasAuthorship W1639292827A5009735463 @default.
• W1639292827 hasAuthorship W1639292827A5018756121 @default.
• W1639292827 hasAuthorship W1639292827A5033070568 @default.
• W1639292827 hasAuthorship W1639292827A5045399615 @default.
• W1639292827 hasAuthorship W1639292827A5078927662 @default.
• W1639292827 hasConcept C126322002 @default.
• W1639292827 hasConcept C127413603 @default.
• W1639292827 hasConcept C164705383 @default.
• W1639292827 hasConcept C177713679 @default.
• W1639292827 hasConcept C2777628954 @default.
• W1639292827 hasConcept C2777698277 @default.
• W1639292827 hasConcept C2777849778 @default.
• W1639292827 hasConcept C2778715236 @default.
• W1639292827 hasConcept C2780645631 @default.
• W1639292827 hasConcept C2780890252 @default.
• W1639292827 hasConcept C49059817 @default.
• W1639292827 hasConcept C500558357 @default.
• W1639292827 hasConcept C71924100 @default.

• next